MedTrace Logo

Comparative Acute Effects of R-MDMA and S-MDMA in Healthy Participants

NCT06905652 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 26

Last updated 2026-05-15

No results posted yet for this study

Summary

Racemic ±3,4-methylenedioxymethamphetamine (MDMA) is a psychoactive substance and prototypical empathogen acutely inducing feelings of heightened mood, empathy, trust and closeness to others. These acute subjective effects of MDMA may be helpful to assist psychotherapy and MDMA has been investigated in phase 3 trials as a possible treatment in post-traumatic stress disorder.

Conditions

  • Healthy

Interventions

DRUG

R-3,4-methylenedioxymethamphetamine

A dose of 300mg enantiomeric R-MDMA will be administered.

DRUG

S-3,4-methylenedioxymethamphetamine

A dose of 100mg enantiomeric S-MDMA will be administered.

OTHER

Placebo

Placebo (Mannitol)

Sponsors & Collaborators

  • University Hospital, Basel, Switzerland

    lead OTHER

Principal Investigators

  • Matthias E Liechti, Prof. Dr. MD · University Hospital, Basel, Switzerland

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
TRIPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-07-29
Primary Completion
2026-05-12
Completion
2026-05-12

Countries

  • Switzerland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06905652 on ClinicalTrials.gov